☆ 4.5 Letter

Glioblastoma immunotherapy: time for hope?

NEUROLOGICAL SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

Persistent mutation burden drives sustained anti-tumor immune responses

Noushin Niknafs et al.

Summary: Genomic analyses reveal a new measure of tumor mutational burden that is associated with therapeutic response to immunotherapy. This measure, called persistent tumor mutation burden (pTMB), is based on mutations in genomic regions that are unlikely to undergo loss. Tumors with high pTMB content show a more inflamed tumor microenvironment and may drive sustained immunologic tumor control in the context of immunotherapy.

NATURE MEDICINE (2023)

Add to Collection

Article Oncology

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma A Phase 3 Prospective Externally Controlled Cohort Trial

Linda M. Liau et al.

Summary: The study shows that adding autologous tumor lysate-loaded dendritic cell vaccine (DCVax L) to standard of care can extend the survival of patients with glioblastoma.

JAMA ONCOLOGY (2023)

Add to Collection

Article Oncology